N-(4-hydroxyphenyl)-4-phenyl-1-piperazineundecanamide | 72232-56-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(4-hydroxyphenyl)-4-phenyl-1-piperazineundecanamide
• 英文别名: N-(4-hydroxyphenyl)-11-(4-phenylpiperazin-1-yl)undecanamide
• CAS: 72232-56-5
• 化学式: C₂₇H₃₉N₃O₂
• 分子量: 437.626
• InChiKey: SBOHUMZSOHGCLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  32
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  55.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  potassium methanolate 、 异丙胺 、 环氧氯丙烷 、 N-(4-hydroxyphenyl)-4-phenyl-1-piperazineundecanamide 在 碳酸氢钠 作用下， 以 甲醇 、 氯仿 、 乙酸乙酯 为溶剂， 生成 (R,S)-N-[4-[3-[(1-methylethyl)amino]-2-hydroxypropoxy]phenyl]-4-phenyl-1-piperazineundecanamide
  参考文献：
  名称：

  (S)-1-[2-

  摘要：

  公开了化合物的结构式如下：##STR1##其中R.sub.1从以下组中选择：较低的烷基；R.sub.8从以下组中选择：--O--(CH.sub.2).sub.n --其中n为2至20，##STR2##和R.sub.6从以下组中选择：氢或较低的烷氧基，以及##STR3##其中R.sub.1从以下组中选择：较低的烷基；R.sub.8从以下组中选择：--O--(CH.sub.2).sub.n --其中n为2至20，##STR4##和R.sub.6从以下组中选择：氢或较低的烷氧基及其外消旋体。还公开了用于生产终端产品的工艺和中间体。这些终端产品可用作同时表现α和选择性β肾上腺素能阻滞作用的试剂。

  公开号：

  US04202978A1
• 作为产物：
  描述：

  N-苯基哌嗪 、 11-bromo-N-(4-hydroxyphenyl)undecanamide 在 三乙胺 作用下， 以 乙醇 为溶剂， 生成 N-(4-hydroxyphenyl)-4-phenyl-1-piperazineundecanamide
  参考文献：
  名称：

  (S)-1-[2-

  摘要：

  公开了化合物的结构式如下：##STR1##其中R.sub.1从以下组中选择：较低的烷基；R.sub.8从以下组中选择：--O--(CH.sub.2).sub.n --其中n为2至20，##STR2##和R.sub.6从以下组中选择：氢或较低的烷氧基，以及##STR3##其中R.sub.1从以下组中选择：较低的烷基；R.sub.8从以下组中选择：--O--(CH.sub.2).sub.n --其中n为2至20，##STR4##和R.sub.6从以下组中选择：氢或较低的烷氧基及其外消旋体。还公开了用于生产终端产品的工艺和中间体。这些终端产品可用作同时表现α和选择性β肾上腺素能阻滞作用的试剂。

  公开号：

  US04202978A1

文献信息

• Intermediate in the production of adrenergic blocking agents
  申请人：Hoffmann-La Roche Inc.

  公开号：US04247710A1

  公开（公告）日：1981-01-27

  There are disclosed compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n --wherein n is 2 to 20, ##STR2## R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy, and ##STR3## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n --wherein n is 2 to 20, ##STR4## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy and racemates thereof. There are also disclosed processes and intermediate utilized to produce the end products. The end products have utility as agents exhibiting both .alpha. and selective .beta. adrenergic blocking action.

  公开了式子为##STR1##的化合物，其中R.sub.1选自低级烷基；R.sub.8选自--O--(CH.sub.2).sub.n --，其中n为2至20，##STR2## R.sub.6选自氢或低级烷氧基，以及##STR3##其中R.sub.1选自低级烷基；R.sub.8选自--O--(CH.sub.2).sub.n --，其中n为2至20，##STR4##而R.sub.6选自氢或低级烷氧基及其外消旋体。还公开了用于生产最终产品的过程和中间体。最终产品作为既具有α又具有选择性β肾上腺素能阻滞作用的药剂具有实用价值。
• Adrenergic blocking agents
  申请人：Hoffmann-La Roche Inc.

  公开号：US04304721A1

  公开（公告）日：1981-12-08

  There are disclosed compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n -- wherein n is 2 to 20, ##STR2## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy, and ##STR3## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n -- wherein n is 2 to 20, ##STR4## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy and racemates thereof. There are also disclosed processes and intermediates utilized to produce the end products. The end products have utility as agents exhibiting both .alpha. and selective .beta. adrenergic blocking action.

  公开了式子##STR1##的化合物，其中R.sub.1选择自低烷基的群体; R.sub.8选择自--O--(CH.sub.2).sub.n --（其中n为2至20），##STR2##和R.sub.6选择自氢或低烷氧基以及##STR3##其中R.sub.1选择自低烷基的群体; R.sub.8选择自--O--(CH.sub.2).sub.n --（其中n为2至20），##STR4##和R.sub.6选择自氢或低烷氧基及其外消旋体。还公开了用于生产最终产品的过程和中间体。最终产品具有作为α和选择性β肾上腺素能阻滞剂的作用。
• Sulfonamide intermediates for adrenergic blocking agents
  申请人：Hoffmann-La Roche Inc.

  公开号：US04281189A1

  公开（公告）日：1981-07-28

  There are disclosed compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n --wherein n is 2 to 20, ##STR2## and ##STR3## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy, and ##STR4## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n --wherein n is 2 to 20, ##STR5## and ##STR6## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy and racemates thereof. There are also disclosed processes and intermediates utilized to produce the end products. The end products have utility as agents exhibiting both .alpha. and selective .beta. adrenergic blocking action.

  公开了化合物的公式，其中R.sub.1选自低烷基的群体; R.sub.8选自--O--（CH.sub.2）.sub.n--其中n为2至20，##STR2##和##STR3##，R.sub.6选自氢或低烷氧基，以及##STR4##其中R.sub.1选自低烷基的群体; R.sub.8选自--O--（CH.sub.2）.sub.n--其中n为2至20，##STR5##和##STR6##，R.sub.6选自氢或低烷氧基及其外消旋体。还公开了用于生产最终产品的过程和中间体。最终产品具有作为α和选择性β肾上腺素能阻滞剂的特性。
• Intermediates for preparing adrenergic blocking agents
  申请人：Hoffmann-La Roche Inc.

  公开号：US04314085A1

  公开（公告）日：1982-02-02

  There are disclosed compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n -wherein n is 2 to 20, ##STR2## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy, and ##STR3## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n -- wherein n is 2 to 20, ##STR4## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy and racemates thereof. There are also disclosed processes and intermediates utilized to produce the end products. The end products have utility as agents exhibiting both .alpha. and selective .beta. adrenergic blocking action.

  公开了化合物的结构式，其中R1选自低碳基；R8选自--O--(CH2)n-，其中n为2到20，以及R6选自氢或低碳氧基，以及其外消旋体。还公开了用于生产最终产品的过程和中间体。最终产品具有作为α和选择性β肾上腺素能阻滞剂的功能。
• 1,4-Disubstituted piperazine compounds
  申请人：Hoffmann-La Roche Inc.

  公开号：US04336382A1

  公开（公告）日：1982-06-22

  There are disclosed compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n --wherein n is 2 to 20, ##STR2## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy, and ##STR3## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n --wherein n is 2 to 20, ##STR4## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy and racemates thereof. There are also disclosed processes and intermediates utilized to produce the end products. The end products have utility as agents exhibiting both .alpha. and selective .beta. adrenergic blocking action.

  公开了化合物的公式 ##STR1## 其中 R.sub.1 选自低级烷基；R.sub.8 选自--O--(CH.sub.2).sub.n --其中n为2至20，##STR2## 以及R.sub.6 选自氢或低级烷氧基，以及##STR3## 其中R.sub.1 选自低级烷基；R.sub.8 选自--O--(CH.sub.2).sub.n --其中n为2至20，##STR4## 以及R.sub.6 选自氢或低级烷氧基和其外消旋体。还公开了用于生产最终产品的过程和中间体。最终产品具有作为既具有α又具有选择性β肾上腺素受体阻滞作用的药剂的效用。